Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol
- PMID: 11804981
- DOI: 10.1161/hc0302.103711
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol
Abstract
When apolipoprotein A-I mimetic peptides synthesized from either D- or L-amino acids were given orally to LDL receptor-null mice, only the peptide synthesized from D-amino acids was stable in the circulation and enhanced the ability of HDL to protect LDL against oxidation. The peptide synthesized from L-amino acids was rapidly degraded and excreted in the urine. When a peptide synthesized from D-amino acids (D-4F) was administered orally to LDL receptor-null mice on a Western diet, lesions decreased by 79%. When added to the drinking water of apoE-null mice, D-4F decreased lesions by approximately 75% at the lowest dose tested (0.05 mg/mL). The marked reduction in lesions occurred independent of changes in total plasma or HDL-cholesterol.
Similar articles
-
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.Circulation. 2004 Jun 29;109(25):3215-20. doi: 10.1161/01.CIR.0000134275.90823.87. Epub 2004 Jun 14. Circulation. 2004. PMID: 15197147
-
Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.Curr Opin Investig Drugs. 2003 Sep;4(9):1100-4. Curr Opin Investig Drugs. 2003. PMID: 14582455 Review.
-
Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.Circulation. 2003 Oct 7;108(14):1735-9. doi: 10.1161/01.CIR.0000089375.60050.35. Epub 2003 Sep 22. Circulation. 2003. PMID: 14504179
-
An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1932-7. doi: 10.1161/01.ATV.0000174589.70190.e2. Epub 2005 Jun 16. Arterioscler Thromb Vasc Biol. 2005. PMID: 15961700
-
Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.Curr Opin Lipidol. 2004 Dec;15(6):645-9. doi: 10.1097/00041433-200412000-00004. Curr Opin Lipidol. 2004. PMID: 15529023 Review.
Cited by
-
A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE-/- mice.Br J Pharmacol. 2020 Oct;177(20):4627-4644. doi: 10.1111/bph.15213. Epub 2020 Sep 9. Br J Pharmacol. 2020. PMID: 32726461 Free PMC article.
-
Apolipoprotein mimetic peptides: a new approach for the treatment of asthma.Front Pharmacol. 2012 Mar 9;3:37. doi: 10.3389/fphar.2012.00037. eCollection 2012. Front Pharmacol. 2012. PMID: 22408624 Free PMC article.
-
Molecular regulation of HDL metabolism and function: implications for novel therapies.J Clin Invest. 2006 Dec;116(12):3090-100. doi: 10.1172/JCI30163. J Clin Invest. 2006. PMID: 17143322 Free PMC article. Review.
-
Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages.Am J Physiol Cell Physiol. 2010 Jun;298(6):C1538-48. doi: 10.1152/ajpcell.00467.2009. Epub 2010 Mar 10. Am J Physiol Cell Physiol. 2010. PMID: 20219948 Free PMC article.
-
Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice.J Lipid Res. 2010 Dec;51(12):3491-9. doi: 10.1194/jlr.M006916. Epub 2010 Sep 14. J Lipid Res. 2010. PMID: 20841495 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous